Skip to main content

zilucoplan

Generic: ZILUCOPLAN SODIUM·Brand: ZILBRYSQ, Zilbrysq

zilucoplan: sourced relationships with 1 company · 5 clinical trials tracked.

zilucoplan evidence translation

What we can confirm

What it means

Source-backed records connect zilucoplan to RARX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could zilucoplan → RARX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
RA PHARMACEUTICALS, INC. (RARX)
developer · Reported 2019-03-07 · Current development: unknownSource
Myasthenia Gravis, Generalized
Phase 3
Clinical Trial Registry Records (5)

A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis

NCT06055959Registry updated 2026-05-08·Phase 2/Phase 3
Recruiting

Primary endpoint: Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29)

Interventionalopen8 targetStarted 2024-10Completion 2026-129 sites · Italy, Poland, South Korea, United Kingdom…UCB Biopharma SRL

A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan

NCT05514873Registry updated 2025-09-03·Phase 3
Completed

Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Main Treatment Period

Interventionalopen26 enrolledStarted 2022-10Completion 2024-1012 sites · United StatesUCB Biopharma SRL

HEALEY ALS Platform Trial

NCT04297683Registry updated 2026-07-21·Phase 2/Phase 3
Active, not recruiting

Primary endpoint: Disease Progression

InterventionalRandomizedquadruple1,500 targetStarted 2020-06Completion 2028-0850 sites · United StatesMerit E. Cudkowicz, MD

A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04225871Registry updated 2026-04-24·Phase 3
Active, not recruiting

Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs)

Interventionalopen200 targetStarted 2019-12Completion 2026-0650 sites · Canada, France, Germany, Italy…UCB Biopharma SRL

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04115293Registry updated 2025-07-16·Phase 3·RARX
Completed

Primary endpoint: Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score

InterventionalRandomizedquadruple174 enrolledStarted 2019-09Completion 2021-1250 sites · Canada, France, Germany, Italy…Ra Pharmaceuticals, Inc.

Frequently asked questions

Which companies have sourced relationships with zilucoplan?

zilucoplan has dated SEC/FDA relationship records for RA PHARMACEUTICALS, INC..

How many clinical trials involve zilucoplan?

BioSniper tracks 5 clinical trials involving zilucoplan.